



Federal Employee Program. **ICLUSIG** PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn: Clinical Services  
Fax: 1-877-378-4727

Patient Information (required)				Provider Information (required)		
Date:				Provider Name:		
Patient Name:				Specialty:	NPI:	
Date of Birth:	Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female			Office Phone:	Office Fax:	
Street Address:				Office Street Address:		
City:	State:	Zip:		City:	State:	Zip:
Patient ID:	R			Physician Signature:		
<b>PHYSICIAN COMPLETES</b>						

**Iclusig (ponatinib)**

**\*\*Check [www.fepblue.org/formulary](http://www.fepblue.org/formulary) to confirm which medication is part of the patient's benefit**

**NOTE: Form must be completed in its entirety for processing**

Is this request for brand or generic? ☐ Brand ☐ Generic

Will the patient need more than 45 milligrams per day? ☐ Yes\* ☐ No

**\*If YES**, please specify the requested milligrams per day: \_\_\_\_\_ mg per day

1. What is the patient's diagnosis?

☐ Accelerated phase (AP) or blast phase (BP) chronic myeloid leukemia (CML)

a. Is the patient eligible for other tyrosine kinase (TKI) therapy? ☐ Yes ☐ No

☐ Chronic phase (CP) chronic myeloid leukemia (CML)

a. Is the disease considered to be resistant or intolerant to two prior tyrosine kinase inhibitors (TKI)? ☐ Yes ☐ No

☐ Newly-diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

a. Will the requested medication be used in combination with chemotherapy? ☐ Yes ☐ No

☐ Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

a. Does the patient have the T315I positive mutation? ☐ Yes ☐ No

b. Is the patient eligible for other tyrosine kinase (TKI) therapy? ☐ Yes ☐ No

c. Will the requested medication be used as monotherapy? ☐ Yes ☐ No

☐ T315I-positive chronic myeloid leukemia (CML)

☐ T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

a. Will the requested medication be used as monotherapy? ☐ Yes ☐ No

☐ Other (*please specify*): \_\_\_\_\_

2. Does the prescriber agree to monitor the patient's complete blood count (CBC)? ☐ Yes ☐ No

3. **FEMALE Patient:** Is the patient of reproductive potential? ☐ Yes\* ☐ No

**\*If YES**, will the patient be advised to use effective contraception during treatment with Iclusig and for 3 weeks after the final dose? ☐ Yes ☐ No

4. Has the patient been on this medication continuously for the last **6 months** excluding samples? **Please select answer below:**

☐ **NO** - this is **INITIATION** of therapy, please answer the following questions:

a. Does the prescriber agree to monitor for evidence of thromboembolism and vascular occlusion? ☐ Yes ☐ No

b. Does the prescriber agree to monitor cardiac function? ☐ Yes ☐ No

c. Does the prescriber agree to monitor hepatic function? ☐ Yes ☐ No

d. **T315I-Positive CML Diagnosis:** Was the patient diagnosed with CML at least six months prior to this request? ☐ Yes ☐ No

☐ **YES** - this is a PA renewal for **CONTINUATION** of therapy, please answer the following questions:

a. Has the patient experienced any thromboembolic events or vascular occlusions while being treated with Iclusig? ☐ Yes ☐ No

b. Has the patient developed heart failure while being treated with Iclusig? ☐ Yes ☐ No

c. Has the patient developed hepatotoxicity while being treated with Iclusig? ☐ Yes ☐ No



Federal Employee Program.

**ICLUSIG**  
**PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn: Clinical Services  
Fax: **1-877-378-4727**

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

<b>Electronically Online</b> (ePA) <b>Results in 2-3 minutes</b> <b>FASTEST AND EASIEST</b>	Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA</b> .
<b>Phone</b> (4-5 minutes for response)	The FEP Clinical Call Center can be reached at <b>(877)-727-3784</b> between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
<b>Fax</b> (3-5 days for response)	Fax the attached form to <b>(877)-378-4727</b> . Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. <b><u>Please only fax the completed form once as duplicate submissions may delay processing times.</u></b>

<b>faster... easier... better...</b>	Introducing ePA! Online Prior Authorizations in minutes through <b>Caremark.com/ePA</b> . Sign up today!
	<b>CVS/caremark</b> 